GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Aidea Pharmaceutical Group Co 688488.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

11.94

+1.44%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥720.7m

FY2016FY2025

Net income

−CN¥19.7m

FY2016FY2025

Free cash flow

−CN¥30.3m

FY2016FY2025

Shareholders' equity

CN¥964.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥720.7mCN¥417.8mCN¥411.4mCN¥244.2mCN¥255.7mCN¥289.1mCN¥345.2mCN¥276.9mCN¥136.3mCN¥257.8m
Gross profitCN¥720.7mCN¥193.3mCN¥166.4mCN¥72.0mCN¥74.4mCN¥143.8mCN¥146.2mCN¥109.0mCN¥39.8mCN¥121.8m
Research and developmentCN¥87.4mCN¥103.3mCN¥63.2mCN¥63.9mCN¥47.7mCN¥26.3mCN¥27.9mCN¥37.8mCN¥37.7mCN¥18.9m
Operating incomeCN¥47.7m−CN¥153.0m−CN¥81.7m−CN¥141.1m−CN¥43.8mCN¥49.6mCN¥39.5mCN¥8.2m−CN¥44.7mCN¥17.8m
Net income−CN¥19.7m−CN¥141.2m−CN¥76.1m−CN¥124.1m−CN¥30.0mCN¥39.8mCN¥33.6mCN¥8.6m−CN¥38.0mCN¥14.2m
Diluted earnings per share-0.04-0.37-0.16-0.33-0.040.080.110.02-0.070.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.91bnCN¥1.87bnCN¥1.75bnCN¥1.66bnCN¥1.43bnCN¥1.45bnCN¥781.0mCN¥708.9mCN¥659.2mCN¥443.6m
Cash and short-term investments—CN¥441.5mCN¥441.1mCN¥486.5mCN¥606.0mCN¥781.0mCN¥129.7mCN¥81.4mCN¥158.5mCN¥32.3m
Total liabilitiesCN¥839.4mCN¥802.5mCN¥621.0mCN¥456.2mCN¥124.8mCN¥87.0mCN¥224.7mCN¥186.2mCN¥145.1mCN¥143.2m
DebtCN¥71.7mCN¥314.8mCN¥412.3mCN¥208.8mCN¥5.6mCN¥15.7mCN¥132.2mCN¥101.0mCN¥60.0mCN¥40.0m
Shareholders' equityCN¥964.7mCN¥980.9mCN¥1.13bnCN¥1.20bnCN¥1.31bnCN¥1.36bnCN¥556.2mCN¥522.7mCN¥514.1mCN¥300.4m
Shares outstanding553m377m473m371m717m481m301m553m553m553m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥17.6m−CN¥37.5m−CN¥166.2m−CN¥92.6m−CN¥12.4mCN¥56.2mCN¥56.2m−CN¥33.5m−CN¥67.2mCN¥31.3m
Capital spending−CN¥47.9m−CN¥44.6m−CN¥71.2m−CN¥140.3m−CN¥94.8m−CN¥42.4m−CN¥33.5m−CN¥89.5m−CN¥85.8m−CN¥71.0m
Free cash flow−CN¥30.3m−CN¥82.1m−CN¥237.4m−CN¥232.9m−CN¥107.2mCN¥13.7mCN¥22.7m−CN¥123.0m−CN¥153.0m−CN¥39.7m
Dividends paid−CN¥20.9m−CN¥15.9m−CN¥11.7m−CN¥3.5m−CN¥20.2m−CN¥3.1m−CN¥5.6m−CN¥3.2m−CN¥1.1m−CN¥12.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥187.8mCN¥178.0mCN¥168.3mCN¥189.9mCN¥164.6mCN¥197.9mCN¥118.9mCN¥117.8m
Gross profitCN¥119.4mCN¥120.2mCN¥357.6mCN¥128.2mCN¥112.1mCN¥122.7mCN¥35.4mCN¥75.4m
Operating incomeCN¥31.8mCN¥20.5mCN¥19.3m−CN¥3.6mCN¥276,664CN¥31.8m−CN¥87.5m−CN¥18.5m
Net incomeCN¥15.3mCN¥7.6m−CN¥12.9m−CN¥16.0m−CN¥6.4mCN¥15.6m−CN¥80.3m−CN¥15.5m
Diluted earnings per share0.030.01-0.02-0.03-0.010.03-0.21-0.04
Cash from operations———CN¥3.0m−CN¥15.0mCN¥39.0m—CN¥78.0m
Capital spending−CN¥18.0m−CN¥7.0m−CN¥29.0m−CN¥1.0m−CN¥6.0m−CN¥10.0m−CN¥3.0m−CN¥15.0m
Free cash flow———CN¥2.0m−CN¥21.0mCN¥29.0m—CN¥63.0m
Total assetsCN¥1.98bnCN¥2.06bnCN¥1.91bnCN¥1.84bnCN¥1.92bnCN¥1.90bnCN¥1.87bnCN¥1.93bn
Cash and short-term investments———CN¥421.2mCN¥472.9mCN¥452.9mCN¥441.5mCN¥472.4m
DebtCN¥325.2mCN¥231.2mCN¥71.7mCN¥427.8mCN¥416.9mCN¥363.5mCN¥311.0mCN¥305.0m
Shareholders' equityCN¥914.8mCN¥974.5mCN¥964.7mCN¥978.0mCN¥989.8mCN¥996.4mCN¥980.9mCN¥1.07bn

Financial ratios

Data as of 11 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin100.0%46.3%40.4%29.5%29.1%49.8%—
Operating margin3.4%-36.0%-19.5%-56.7%-16.4%17.4%—
Net margin-2.7%-33.8%-18.5%-50.8%-11.7%13.8%—
Return on equity-2.0%-14.4%-6.8%-10.3%-2.3%2.9%—
Return on assets-1.0%-7.6%-4.4%-7.5%-2.1%2.7%—
Free cash flow yield0.8%0.1%-1.3%0.8%0.7%1.3%—
Revenue growth72.5%1.6%68.4%-4.5%-11.5%-16.3%—
Earnings growth-86.0%85.6%-38.7%313.8%-175.4%18.2%—
Current ratio1.32x1.38x1.77x2.42x8.94x13.79x—
Debt to equity0.07x0.32x0.36x0.17x—0.00x0.24x
Equity ratio50.4%52.5%64.4%72.4%91.3%94.0%—
Interest coverage1.56x-9.72x-6.83x-34.54x-125.12x16.69x—
R&D as a share of sales12.1%24.7%15.4%26.2%18.6%9.1%—
Buybacks as a share of market value-46.5%20.3%-27.4%48.2%-49.1%-59.9%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue43.4%20.0%—
Operating income—-0.7%—
Net income-45.8%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin80.3%64.2%58.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-457.3-21.0-77.8-31.5-372.5300.1
Price to sales12.57.114.416.043.741.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 24 Jun 2021.

FY2021
Paid in the year0.048

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.